- Home
- THAR vs TOVX Comparison
THAR vs TOVX Comparison
Compare THAR & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THAR | TOVX |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 7.3M |
| IPO Year | 2022 | 2006 |
Fundamental Metrics
Financial Performance| Metric | THAR | TOVX |
|---|---|---|
| Price | $2.39 | $0.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 292.1K | ★ 2.6M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.20 |
| 52 Week High | $9.08 | $2.08 |
Technical Indicators
Market Signals| Indicator | THAR | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.25 | 42.02 |
| Support Level | $2.36 | $0.21 |
| Resistance Level | $2.75 | $0.24 |
| Average True Range (ATR) | 0.18 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 8.51 | 25.70 |
Price Performance
Historical ComparisonAbout THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.